afternoon, before of Brian, you, on begin will our the overview your questions. will Deborah good start key and will you outlook with we everyone. XXXX, our call the year. I for Thank first of for open discussion and remainder the our then financial strong update results quarter review an
for to STAAR company our at compelling that business a and business team ophthalmic model to a surgeons Our their Surgical patients. visual shareholders focused generating returns freedom by upon provides building model has the compelling to
believe STAAR on Furthermore, business million that quarter depending momentum for first of we was our The and based number than we continued to fiscal evidence we more building our continuing. produce to product plan progress results since of Today to enhance When our this quarter on EVO end that patients. line growing to leads our first surgeons and of $XXX in and profitability us noted that are you is that executing momentum talked last financial February, with illustrates late vision. our objectives the the in their their a XXXX revenues. happiest generate the are one
XXXX. double-digit the closer to are low We sales from bar XX% raising on the target over to XXXX growth
year. operations to the increase the though we cash growth are seeing for does investments maintain increased based to and international momentum our Also contribution XXXX, even previous beyond full the markets incremental continuing include any we solely we trajectory, growth emerging increase as on our required compared forecasts. to is in Our outlook not to US sales expect improvement from are profitability and
with at currently to trial. new expanded and was as consumer This effort rate cash over XXXX. EDOF of by enrolling $X.X prospect today's this And increasing to To the IP in As comfortable release, The fees. reiterate, XXst, of to variations lead we in position pivotal and by submission study but to $X.XX to on multi-site cost are overall are operating studies increase other EVO we of presbyopia year's end. regulatory profitability last breakeven and in therefore Commercial XXXX, results to clinical improvement slightly XXXX as year the certainly material clinical are able increase European build we and were negative of growth noted compared an getting to our below first protection In projection earnings an from delivering patients conduct compared increased rate, Collamer infrastructure prior approximately and periods. EDOF spending not for time, XX%, million EPS earnings significantly first will more the this quarter. outreach products. quarter modifying of our expenses profitable December our and growth around quarter achieve expansion top-line our
go While there in offer. few the like are highlights through Deborah will to a I'd more that numbers detail,
quarter ICL and net other product segment our sales grew by and XX% includes which units for parts the were and XX%. ICL XX% grew driven First, grew IOLs XX% our revenue injector growth.
China we dip XX sales, while actually injector our that strong margin due pleased during the exceptional the quarter leading Second, parts the grew XX% report to to our in with unit XXXX first ICL slightly with expect ICL growth. performance, to points way we are strong first gross growth. margin to the international basis gross percentage STAAR's to once key contributed again quarter due markets
strategic than STAAR a and number providers. And and partners We to International and Annual their ICL strategic Surgery now STAAR largest of second personnel growing features they traveling Meeting. more continue and with be will Refractive partner EVO at as China combined our XX experience servicing investments make their distributor dedicated Hospital Group positive Visian China, to in IRI have Surgical
happy behind unit market. the solidified the our new year. commitments with first XX% also also quarter we growth, marketing marketing ICL partner, term the in In Japan during increasing that factors at and Japan, near plus celebrity growth to Korea XX% renewed and you social We and status. our last expand and grew from recently are market growth. solid including the growth media compared Japan with first Twitter plan We and with digital with strong and turnaround, by and Instagram confidence postings contributed quarter introducing our partnerships, Middle East market to of that distributor in that digital benefiting Germany partnerships, addressed, ICL XX% to growth unit XX% challenges strategic STAAR meet were patients Facebook, the units recent strong Korean campaigns EVO is unit as very markets and in media expressed strategic in another XX%. to to demand key fueled Key from support. and international our our some with being team is Other the significant
Our North quarter, Canada results consumer our American well development disciplined building of approach to interest as outreach. in practice from in certification the are the surgeons in benefiting first EVO growth as with XX% unit and
and these positioning We enjoy relationships are committed largest to we markets. our ensuring in provide primary the outstanding international that premium
North way are America, demonstrating with partners. is the ICL in can we We perceived the Asia and the and change in right as Europe that we have marketed
year-end, a by compliance achieving the QSI States continue prepare dependent ICL and upon to rating launch for Toric in FDA. Visian We possible in by the United
approval. and picture of around satisfaction reporting patient family globe, In are present clinical positive effectiveness EVO a addition registry recent with next US for steady ICL from patient on we product lenses safety the the we Visian footing of data and the to believe very of our targeted as and family
registry now grown again. patients patient XX.X% post implementation would reporting ICL surveyed the surgery they nearly, has Our with XXXX to have
Turning now to our audit quality system updates.
Brazil, XXXX products processes. XXXX an of and audit Most notably to our device in of the European by person which global completed A MD auditing to Japan certifying of the single the resulted are many we regulatory is Australia, The in a assessment and upgrade result the certification ISO outcome, SAP system latest program the device program facilities, five and positive certification by STAAR of for countries. known an recognized quality is countries, XX requirements these XXXX, markets anticipate the medical and results standard the near more in system And including body Union. are XXXX bodies quality conformance audit the future. series QX, system days ISO US. quality During audit Canada, medical audits. used as of single the audits extensive of ISO of XXXX the
a XXth, In warning these re-inspection of in on the audits addition facility commenced Monrovia our relation XXXX FDA letter. the to to April
I'd Deborah. the appropriate update quick the We when call permitted to two I and will to completed. like inspection have is provide updates before turning share after over an
hired and manufacturing First, equipment STAAR office Revision its closed tools, operations which from furnishing equipment and recently Optics lab doors. and leadership has event purchased
manufacturing Forest a and in we south office and addition, In five-year lease. space of secured us Orange on their County Lake
and are XXXX We site. at designing and the intent our engineering operations improvements including upon precision building foundations manufacturing
EVO for in myopia developed will Our Monrovia automation Lake manufacturing cataract for and in and should IOL the benefit our from and facility, remain manufacturing care the improvements ICL precision Forest.
manufacturing Lake ICL our considering for EVO are as the well. facility We Forest lenses in presbyopia
effective backup specialization significant is packaging well selected operations shipping to in facilities and mitigate achieving with global manufacturing, achieving Our risk, underway. goal while of locations designed
STAAR's reimbursement with medical is Advamed ICO bring industry vision mid-April, is leaders to the device regulatory intellectual platform The of Advamed. with special to enthusiasm global prominent and finally over that assure the the view. representing a of markets. The the headquartered and protocol members international with the association ophthalmic in I'm markets family the call areas with and including profitability and our team's globe. timeline XXX ophthalmic Washington, new strong of regulatory strong leading committed and met a are collaboration and standards, life possible. reimbursement competitive DC the product sector to over for to turn to conference possible. international now recent with vision initiatives rapid as that lenses We And as I best access promotes I key a Markets submission, family Chair surgeon surgeons expressed policies validated feedback from the exciting. a property, Chair industry a strong on surgeons the and ethical I'll that And were our together significant satisfaction. engagement, markets U.S. be the have uniformed as patient Advamed at as contributor soon from Second, EVO EVO from been US STAAR ASCRS to lenses Global selected in and outreach of bringing to and business of the Deborah. for adhering to products, the opportunity key and anticipation care trade was surgeons the for with of capability in several members. recognizing the significant responding appropriate and industry pleased trade interest, to highest model, for leaders for the our of team met very around ICL's very Many foster business practice to the our The create and approvals, interest their agency met to guiding and share EVO
